Name PI: Arjan Griffioen, Else Huijbers
Department, UMC: Medical Oncology, VUMC
Size of research group: 18

**Current mission, vision and aims**
To unravel the fundamental processes and mechanisms underlying angiogenesis and vascular development. The major aim is to use new knowledge and technology for the development of new treatment modalities in the clinic.

Line I: Target and drug discovery
Line II: Cancer vaccines
Line III: Combination therapies
Line IV: Personalized treatment strategies
Focus of research group (II)

Current expertise

Target finding in the tumor vasculature
Vaccine & antibody development
In vitro/in vivo angiogenesis assays
Mouse tumor models

Current funding

KWF preventive vaccine 780.000 euro
KWF vimentin 450.000 euro
KWF magic combination 450.000 euro
KWF galectins 175.000 euro
Preseed grant government 200.000 euro
Future plans

**Short term (1-2 year) plan**
Plan: Development of 1. an angiostatic cancer vaccine, 2. a multi-targeted vaccination approach, 3. a preventive cancer vaccine, 4. an optimal vaccination combination therapy.

Necessary infrastructure: fluorescence microscopy, in vivo imaging, FACS sorter.

**Long term (>2 year) plan**
Plan: Vaccine development in advanced mouse models. Phase I clinical testing.

Necessary infrastructure: Animal facility, PET/MRI, phase I unit.

Plan: Further establish CimCure BV.